NG
IONS icon

NWK Group’s Ionis Pharmaceuticals IONS Stock Holding History

NWK Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-825
Closed -$49K – 219
2020
Q2 		$49K Buy
825
+75
+10% +$4.17K 0.03% 95
2020
Q1 		$35K Buy
750
+100
+15% +$5.57K 0.03% 95
2019
Q4 		$39K Buy
+650
New +$38.7K 0.03% 108

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

NWK Group's IONS Position: Q3 2020 in Review

NWK Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 825 shares — an estimated $49K sold.

NWK Group first reported a position in IONS in Q4 2019 and held it in 3 quarters. The position peaked at $49K in Q2 2020. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • NWK Group reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • NWK Group sold 825 Ionis Pharmaceuticals shares in Q3 2020, an estimated $49K.
  • NWK Group first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • NWK Group's Ionis Pharmaceuticals position peaked at $49K in Q2 2020.
  • 367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on NWK Group's 13F filing for Q3 2020, filed 16 Nov 2020.